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We thank Dr Andresdottir1 for their comments. We fully
accept that membranoproliferative glomerulonephritis
(MPGN) types I and II are different in many ways,
although the comparison with focal segmental glomerulo-
sclerosis and membranous nephropathy is not accurate.
Both type I and II MPGNs are characterized by immune
complex deposition with a membranoproliferative pattern
of injury by light microscopy, associated clinically with
slowly progressive nephritis, proteinuria, and hypocom-
plementemia. It is thus reasonable, until a definitive
etiology is identified, to consider them together.
We also accept that clinically silent recurrence may
occur, although this was not evident on those recipients
who underwent biopsy for other indications such as
rejection. We felt, however, that clinical recurrence was a
more clinically relevant outcome to include in the multi-
variate analysis. Seven allografts were donated by a family
member, of which four (57%) developed recurrence (two
each in the MPGN types I and II groups). This value was
not significantly different from that seen in the group as a
whole (49%), although the numbers here are too small to
exclude a subtle effect.
With respect to repeated transplantation, identified as a
risk factor for recurrence in MPGN type I in Dr
Andresdottir and colleagues’ series of five patients, we
have re-analyzed our data. In our series, of the seven cases
re-transplanted, two were in the MPGN type I group and
neither of these developed recurrence, indicating that (in
our series) this is not predictive in re-transplantation. They
also state that crescents on the original biopsy were not
predictive of recurrence of type II MPGN. Unfortunately,
these data were not present in their published paper, so we
are unable to comment on this.
We certainly do not dispute the large body of evidence
indicating that patients with type II MPGN are more likely
to develop recurrent disease than other forms of MPGN.
Rather, we maintain that it is the presence of severe
histological features of crescentic glomerulonephritis
(which are over-represented in MPGN type II patients)
that have the most potent impact on recurrence.
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